NCT07467447: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
- State
- Under way
- Phase
- Phase 2
- People
- 300 planned
- Started
- 15 Feb 2026
- Primary completion
- 14 Mar 2027
- Arms
- Retatrutide (LY3437943) 1 mg once weekly (no escalation), Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg., Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation)., Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg, Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg., Placebo once weekly (matched escalation schedule to maintain blinding)., Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.
- Results
- None posted
- 15 Feb 2026: Trial started
- 12 Mar 2026: Trial registered